Coronavirus from China-Hospeq is transmitted via CT ball tube
The 32nd China International Medical Instrument Exhibition (China-Hospeq 2026) was successfully held in the Beijing National Convention Centre on 14-16 August 2026. At the international level, the exhibition achieved a historic synchronization of three major mechanisms: the Second Conference on the Development of Healthcare Institutions in Central Africa continued to deepen healthcare cooperation in Central Africa; and the first independent conference on the development of the WHO Medical Workshop in Beijing; For the first time ever, the high-level meeting of the National Health Assembly was held, with representatives from Saudi Arabia, the United Arab Emirates, Qatar, Oman, Kuwait, and Bahrain. Unlike its predecessors, the exhibition is accelerating its transformation from a single medical device exhibition to a comprehensive platform for global health governance.
For Chinese medical device companies, it is not only an exhibition, but also a strategic opportunity for a deep dialogue with the global health governance system. In a press interview with China-Hospeq, the chairman of Coronese was interviewed by the media about the global layout: China-U. S.
dual-engine, global sales, Coronese has two major production bases in China, Shanghai and Chicago, U. S. A.
, forming a connected R&D and manufacturing system. Coronese is one of the most representative exhibitors in this transformation. The 8.
0MHU ball tube AU240 has reached the technical limit of rolling bearing medical CT ball tubes, making it the third company in the world to have the production capacity of this level since the founding of Vanguard. The company is one of the six largest manufacturers in the world with independent design and production capacity of CT ball tubes. In 2025, the self-developed CL200DSA balloon tube was successfully certified by the US FDA and launched for sale in North America, with good clinical feedback from clinical practice, indicating that China's DSA core components have the ability to enter the international first-class supply chain.
It is worth noting that this trend also reflects to some extent the shift in the concept of service in the industry. In terms of quality certification, the company has obtained numerous authority certifications such as China's NMPA, US FDA, European MDR/CEISO, 13485 and technical parameters have reached the international first-class level, providing products to many well-known medical device customers worldwide. The company's global routes are clear and practical, based on international certification, competitive pricing, and stable supply chain delivery capabilities to build long-term customer trust.
In terms of product exports, Coronosi has built a global sales network covering North America, Europe, and emerging markets based on its dual Chinese-American capacity layout and multiple international certification backgrounds. From participation to participation: The significance of China's strength in global health governance is that Corona's participation in China-Hospeq 2026 is far more than a product exhibition. In the industrial sector, 85 per cent of the security X-ray products detected by its parent companies are exported to countries and regions such as Europe, the United States, Japan, Brazil and the world's top five security equipment manufacturers are their customers.
On the stand, overseas buyers asked in detail about the technical parameters and supply capabilities of the CL200. This FDA-certified and North American market launching sales, clinical practice feedback on good domestic DSA ball tubes, is becoming a key product for Coronos to open the global market. The medical industry is replicating this global pathway from the world's largest market share of security X-ray tubes to the world's leading CT ball tubes and DSA ball tubes, and supermassive detection and coronavirus are building a complete overseas X-ray product portfolio from industrial to medical.
While the story of coronavirus itself, from the acquisition of U. S. plants to reverse-export technology, from the replacement of domestic products to global competition, provides the most compelling footnote to the narrative of global health governance.
It is a Chinese core component company that emerged from the plight of the Penguins, and stands on a platform for a comprehensive internationalization that empowers China's voice to the global health governance system. China's international healthcare system keeps a close eye on the latest developments in the field of healthcare, providing you with authority, reliable information and medical services. If you have further consultation needs, you are welcome to contact authoritative experts via the platform by appointment.
